EGFR and lung carcinoma: Drug sensitivity assay showed that GLI2 overexpression significantly (p < 0.01) enhanced drug resistance of lung cancer cells against targeted EGFR inhibitors and conventional chemotherapy drugs (Fig. S7A and Table S7).